Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Operating cash flow minus capital expenditures
Latest
$-52.26M
↓ 77% vs avg
Percentile
P8
Near historical low
Streak
3 yr
Consecutive declineContracting
Average
$-29.58M
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | $-52.26M | -6.5% |
| 2024 | $-49.06M | -59.1% |
| 2023 | $-30.84M | -14.9% |
| 2022 | $-26.85M | +62.2% |
| 2021 | $-71.00M | -74.9% |
| 2020 | $-40.60M | -109.3% |
| 2019 | $-19.40M | -425.3% |
| 2018 | $-3.69M | -129.5% |
| 2017 | $12.50M | +185.5% |
| 2016 | $-14.61M | - |